– USA, CO – Think Bioscience, a synthetic biology company focused on developing small-molecule therapeutics that target difficult-to-drug proteins, today announced the appointment of Dr. Nicholas Saccomano (Ph.D.) to its Board of Directors.
“Dr. Saccomano is an experienced and passionate drug developer. He will be an invaluable resource to Think Bioscience as we expand our drug discovery platform and advance our internal drug development programs. His passion for developing medicines combined with his industry knowledge will make him an important addition to the Board of Directors,” said co-founder and CEO, Dr. Jerome Fox.
About Dr. Nicholas A. Saccomano
Dr. Saccomano is a seasoned pharmaceutical professional with 30+ years of extensive research and development experience across multiple therapeutic areas.
Dr. Saccomano currently serves on the board of OnKure Therapeutics, a clinical-stage biotech company, and advises several growing bioscience companies. Previously, Dr. Saccomano worked at Pfizer R&D, Inc. as CSO and Site Head at its Boulder facility, where he led a 170-person research and development team that advanced a portfolio of small molecule drug programs from inception to proof-of-concept. Before working at Pfizer, he served as CSO at Array Biopharma Inc., where he was responsible for creating and advancing ten clinical-stage compounds, with seven drug approvals to date.
“Think’s pioneering chemical biology approach to small molecule drug discovery leverages the immense chemical diversity of biosynthetic pathways; it shows great promise for discovering new molecular pharmacology and developing important drugs against difficult and novel targets,” said Dr. Saccomano. “I look forward to working closely with the Think Bioscience team.”
Dr. Saccomano received a B.S. from the State University of New York at Buffalo and a Ph.D. in Organic Chemistry from Columbia University under the direction of Gilbert Stork.
About Think Bioscience
Think Bioscience is reimagining synthetic biology by using living systems to guide the design and assembly of better medicines. The unique approach to drug discovery combines applied microbiology, enzymology, and computational science to develop small-molecule therapeutics against elusive targets.
For more information: https://thinkbioscience.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
